Rusan Pharma gets DCGI nod to APOSAN for treating Parkinsons Disease
Rusan Pharma said it has developed the drug, which would be available in the form of injections, pen and continuous infusion pumps, indigenously and has received approval from the Drug Controller General of India (DCGI).
New Delhi: Drug maker Rusan Pharma recently said it has launched a drug to treat Parkinson's disease. The drug -- Aposan -- is used to treat motor fluctuations in patients with Parkinson's Disease which are not sufficiently controlled by oral medications currently available in the country.
The company said it has developed the drug, which would be available in the form of injections, pen and continuous infusion pumps, indigenously and has received approval from the Drug Controller General of India (DCGI).
"The company has always put forward indigenously developed high technology advanced delivery products in the Indian market," Rusan Pharma MD Kunal Saxena said in a statement.
The company wants to ensure that the treatment is affordable and accessible to all Parkinson's disease patients, he added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd